ArticleScientific reports2025
Tracing micro and nanoplastics toxicity in human pulmonary fibroblasts through integrated Raman and transcriptomic analyses.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Microplastics and nanoplastics in human toxicity: ROS-mediated mechanisms, cellular damage and systemic effects.Molecular biology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inhaled micro- and nanoplastics can reach the distal regions of the lungs, where their elimination is limited due to the lack of efficient clearance mechanisms. Although polystyrene particles have been detected in human lung tissue, the molecular effects of such exposures remain poorly characterized. Understanding the cellular response to microplastics exposure, particularly at the transcriptional and structural levels, is essential for assessing potential health risks. The purpose of this study was to evaluate the impact of primary polystyrene micro- and nanoparticles on human pulmonary fibroblasts, a relevant in vitro model for investigating the molecular mechanisms underlying microplastics-induced pulmonary toxicity. Monodisperse polystyrene particles with diameters of 0.1, 1 and 5 μm were used to evaluate size-dependent internalization and cellular response in human pulmonary fibroblasts. Cells were cultured under standard conditions and exposed to particles in vitro. Internalization and fate of microplastics were tested using Raman microscopy, while transcriptomic alterations were assessed by RNA sequencing to identify early molecular responses associated with particle size. Raman microscopy confirmed the internalization of 0.1 μm polystyrene particles by human pulmonary fibroblasts. Particles sized 1 μm showed a high affinity for the fibroblast cell membrane, however, definitive confirmation or exclusion of their internalization into the cells was not possible due to the sample preparation protocol and measurement conditions used. In contrast, exposure to 5 μm particles resulted in pronounced cytotoxicity across tested concentrations, precluding RNA-seq analysis. Transcriptomic profiling assessed by principal component analysis revealed distinct gene expression patterns in cells following exposure to 0.1 and 1 μm particles. Exposure to 0.1 μm particles led to upregulation of genes involved in mitochondrial function and protein synthesis. In contrast, 1 μm particles caused downregulation of genes associated with oxidative phosphorylation and proteostasis. This study shows that particle size and concentration critically influence the molecular response of human pulmonary fibroblasts to polystyrene micro- and nanoparticles. Raman microscopy proved a valuable tool for detecting particle internalization and assessing size-related biochemical changes, including in the nanoscale range.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.